1,437 reports of this reaction
4.5% of all BENRALIZUMAB reports
#3 most reported adverse reaction
DEATH is the #3 most commonly reported adverse reaction for BENRALIZUMAB, manufactured by AstraZeneca Pharmaceuticals LP. There are 1,437 FDA adverse event reports linking BENRALIZUMAB to DEATH. This represents approximately 4.5% of all 31,657 adverse event reports for this drug.
Patients taking BENRALIZUMAB who experience death should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEATH is moderately reported among BENRALIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to death, the following adverse reactions have been reported for BENRALIZUMAB:
The following drugs have also been linked to death in FDA adverse event reports:
DEATH has been reported as an adverse event in 1,437 FDA reports for BENRALIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEATH accounts for approximately 4.5% of all adverse event reports for BENRALIZUMAB, making it one of the most commonly reported side effect.
If you experience death while taking BENRALIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.